Additional research to the "Phase II Nab-Paclitaxel + Ramucirumab + Nivolumab in Unresectable Advanced or Recurrent Gastric Cancer Refractory to First-Line Therapy Including Pyrimidine Fluoride, Platinum, and Anti-PD-1/PD-L1 Antibodies (PADDLE)" study

Additional research to the "Phase II Nab-Paclitaxel + Ramucirumab + Nivolumab in Unresectable Advanced or Recurrent Gastric Cancer Refractory to First-Line Therapy Including Pyrimidine Fluoride, Platinum, and Anti-PD-1/PD-L1 Antibodies (PADDLE)" study - Additional research to PADDLE study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050765

Enrollment

Registered

2023-04-11

Start date

2022-12-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable advanced or gastric cancer who participated in the PADDLE study

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Effects of drug therapy on immune profiling and gene expression in tumor tissue or peripheral blood, and their interrelationship with therapeutic effects	—

Countries

Japan

Contacts

Public ContactHidekazu Hirano

National Cancer Center Hospital Department of Gastrointestinal Medical Oncology

hihirano@ncc.go.jp03-3542-2511

Outcome results